February 3, 2010 (FinancialWire) — Fibrocell Science, Inc. (OTCBB: FCSC) has named David Pernock, chairman of the company’s board of directors, as chief executive officer. Pernock most recently served as senior vice president, Pharmaceuticals, Vaccines, Oncology, Acute Care and HIV at GlaxoSmithKline. He joined Fibrocell’s board of directors last September.

Pernock formerly worked at GlaxoSmithKline (NYSE: GSK), during a career that culminated with his role as SVP.

Fibrocell Science is a biotechnology company focused on developing regenerative fibroblast cell therapy for aesthetic, medical and scientific applications.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.